Cited by 25Growth Hormone and Insulin-like Growth FactorsBone health and osteoporosis researchHormonal and reproductive studies

Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender

Rota, F., Savanelli, M. C., Tauchmanova, L., Savastano, S., Lombardi, G., Colao, A., Di Somma, C.·2008·Journal of Endocrinological Investigation

Abstract

GH deficiency (GHD) in adults is accompanied by reduced bone mass that may revert only after 2 yr of GH replacement. However, it is unclear whether the gender may modify bone responsiveness to GH replacement in adults. In this study we have evaluated whether bone mineral density (BMD) and turnover improve after GH replacement according to patients' gender. BMD at lumbar spine (LS) and femoral neck (FN), serum osteocalcin (OC), and urinary cross-linked N-telopeptides of type I collagen (Ntx) were assessed in 64 hypopituitaric patients (35 men, 30-50 yr) before and 2 yr after the beginning of GH replacement. Values of IGF-I and BMD at LS and at FN were expressed as Zscores. At study entry, IGF-I and BMD resulted similar among men and women with GHD. During GH replacement, IGF-I levels increased in both men and women without any difference in the percentage of IGF-I increase between the genders (p=0.47). In women receiving estrogen replacement, however, the percentage of IGF-I increase (p<0.05), and the Z IGF-I score (p<0.001) were significant lower than estrogen untreated women, although IGF-I levels were similar in the 2 groups (p=0.53). The GH dose adjusted for body weight required to restore normal age- and sex- matched IGF-I levels was lower in men than in women (p<0.001), and was higher in women receiving than in those not receiving estrogen replacement (p<0.05). In contrast, hypogonadal men treated with testosterone and eugonadal men received a similar GH dose (p=0.97). A…

Integrity signals

Registry

Crossref · 10.1007/bf03345574

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • During rhGH treatment, BMD decreases within the first months and then increases after at least one year of therapy.

    “BMD within the first months of treatment decreased which was followed by a subsequent increase after at least one year of therapy.”

    From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [58]

  • GH replacement promotes bone turnover by stimulating both bone formation and bone resorption, which is prominent during the first phase of GH treatment.

    “GH replacement promotes bone turnover by stimulating both bone formation and bone resorption, which is prominent during the first phase of GH treatment.”

    From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [58]

  • After the first phase of GH treatment, bone turnover slows down and bone mass increases.

    “After this period bone turnover slows down and bone mass increases [48, 57, 58].”

    From Pituitary Disorders and Osteoporosis (2015) · cites this paper as [58]

Cites

Flagged first, then by citations

1 of the 48 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Rota, F., Savanelli, M. C., Tauchmanova, L., Savastano, S., Lombardi, G., Colao, A., & Di Somma, C.
Affiliations
  • University of Naples Federico II (IT)
  • Federico II University Hospital (IT)
Corresponding author
Colao, A.
Venue
Journal of Endocrinological Investigation
Published
2008-02
Volume
31
Issue
2
Pages
94-102
ISSN
  • 0391-4097 (ISSN-L)
  • 1720-8386
OpenAlex
W2026828382
Cited by
25
References
48
Citations by year
2024: 3 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 3 · 2016: 1 · 2015: 1 · 2014: 3 · 2013: 4 · 2012: 1
FWCI
1.45
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Endocrinological Investigation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
Keywords
adult growth hormone deficiency, growth hormone replacement therapy, bone mineral density, bone turnover, sex differences, insulin-like growth factor I, osteocalcin, N-terminal telopeptide of type I collagen, estrogen replacement therapy, testosterone replacement therapy, hypogonadism, hypopituitarism, lumbar spine, femoral neck, young adults
MeSH terms
Adult, Female, Humans, Hypopituitarism, Male, Middle Aged, Peptides, Sex Characteristics, Bone Density, Osteocalcin, Bone Remodeling, Human Growth Hormone, Hormone Replacement Therapy, Collagen Type I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review